Avricore Health Inc. (TSXV:AVCR,OTCQB:AVCRF) was featured in an article by The Canadian Business Quarterly. Avricore Health is a healthcare technology company focused on health innovation in the nutraceutical, medical cannabis and endocannabinoid industries. The company is focused on looking at how pharmacies and pharmacists currently operate so the company can help identify opportunities to enhance services. With the rise of on-demand retail testing, the company believes that pharmacies can take a more significant role in assisting consumers in making informed healthcare decisions.
Avricore Health is expected to grow as the company works to revolutionize direct-to-consumer healthcare further. To date, Avricore Health has developed HealthTab™, a point-of-care screening system that allows patients to directly measure and monitor the 21 key biomarkers of chronic disease. The system utilizes Abaxis’ Piccolo Xpress® point of care analyzer, which was initially designed by NASA to test the health of astronauts. The company has installed its technology in pharmacies in British Columbia, Alberta and Ontario so far and will be rolling out its technology in up to 200 locations within 18 months.
According to the article, technological innovations are giving shape to pharmacogenomics and how genetics play a role in an individual’s response to drugs. Data from the US Food and Drug Administration (FDA) shows that over 260 therapeutic agents have information on how genes affect them, and this number is expected to grow. The advancements in the pharmacogenomics market are on track to reach $10.2 billion by 2025. Healthcare practitioners are in favor of the trend due to its potential to better serve patients and consumers.
To read the full article, click here.